These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

370 related items for PubMed ID: 22995071

  • 21. Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model.
    Wang L, Chen H, Pourgholami MH, Beretov J, Hao J, Chao H, Perkins AC, Kearsley JH, Li Y.
    PLoS One; 2011; 6(9):e24405. PubMed ID: 21931707
    [Abstract] [Full Text] [Related]

  • 22. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells.
    Edwards A, Li J, Atadja P, Bhalla K, Haura EB.
    Mol Cancer Ther; 2007 Sep; 6(9):2515-24. PubMed ID: 17876048
    [Abstract] [Full Text] [Related]

  • 23. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo.
    Sanchez E, Shen J, Steinberg J, Li M, Wang C, Bonavida B, Chen H, Li ZW, Berenson JR.
    Leuk Res; 2011 Mar; 35(3):373-9. PubMed ID: 20650529
    [Abstract] [Full Text] [Related]

  • 24. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies.
    Qian X, LaRochelle WJ, Ara G, Wu F, Petersen KD, Thougaard A, Sehested M, Lichenstein HS, Jeffers M.
    Mol Cancer Ther; 2006 Aug; 5(8):2086-95. PubMed ID: 16928830
    [Abstract] [Full Text] [Related]

  • 25. PP242 synergizes with suberoylanilide hydroxamic acid to inhibit growth of ovarian cancer cells.
    Qin Y, Zhao X, Fang Y.
    Int J Gynecol Cancer; 2014 Oct; 24(8):1373-80. PubMed ID: 25188886
    [Abstract] [Full Text] [Related]

  • 26. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
    Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, Sanni T, Atadja P, Pili R.
    Clin Cancer Res; 2006 Jan 15; 12(2):634-42. PubMed ID: 16428510
    [Abstract] [Full Text] [Related]

  • 27. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.
    Hussain AR, Al-Romaizan M, Ahmed M, Thangavel S, Al-Dayel F, Beg S, Uddin S, Siraj AK, Al-Kuraya KS.
    Mol Med; 2015 May 26; 21(1):466-78. PubMed ID: 26023849
    [Abstract] [Full Text] [Related]

  • 28. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
    Liu M, Bamodu OA, Huang WC, Zucha MA, Lin YK, Wu ATH, Huang CC, Lee WH, Yuan CC, Hsiao M, Deng L, Tzeng YM, Yeh CT.
    Toxicol Appl Pharmacol; 2017 Jun 15; 325():48-60. PubMed ID: 28408137
    [Abstract] [Full Text] [Related]

  • 29. Histone deacetylase inhibitors induce human renal cell carcinoma cell apoptosis through p-JNK activation.
    Xu M, Hong M, Xie H.
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Oct 15; 33(10):1409-15. PubMed ID: 24144737
    [Abstract] [Full Text] [Related]

  • 30. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.
    Rahmani M, Aust MM, Benson EC, Wallace L, Friedberg J, Grant S.
    Clin Cancer Res; 2014 Sep 15; 20(18):4849-60. PubMed ID: 25070836
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells.
    Chen S, Zhao Y, Gou WF, Zhao S, Takano Y, Zheng HC.
    PLoS One; 2013 Sep 15; 8(11):e79781. PubMed ID: 24236158
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
    Mehdi O, Françoise S, Sofia CL, Urs G, Kevin Z, Bernard S, Igor S, Anabela CD, Dominique L, Eric M, Ali O.
    Pancreatology; 2012 Sep 15; 12(2):146-55. PubMed ID: 22487525
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.